The renin-angiotensin system is the most important hormonal system in the control of blood pressure. It can be blocked at several steps in its reaction pathway. Angiotensin-converting enzyme, or kininase /J, is responsible for catalysing the formation of vasoconstrictor angiotensin Il as well as for the breakdown of the vasodilator bradykinin. With the advent of specific orally active angiotensin-converting enzyme inhibitors (captopril and enalapril) a practical and effective means of blocking angiotensin formation is now clinically available. ACE inhibitors are effective long-term therapy in patients with essential hypertension. They are particularly useful in the treatment of severe accelerated drug-resistant hypertension and renovascular hypertension, and the agents of choice for after/oad reduction in severe congestive cardiac failure. They have several pharmacological advantages, important in anaesthetic practice, over other hypotensive agents. They have no central nervous or autonomic nervous system effects. Thus, patients being treated with ACE inhibitors retain normal sympathetic cardiovascular responses.
importance. Similarly, specific renin antibodies have been produced, purified and active Fab fragments isolated. Antibodies active against dog renin and more recently primate renin are now available and have been shown to be effective in vivo. 2 ,4 These have been shown to lower the blood pressure in high renin states (sodium depletion, acute renal artery stenosis). However, they introduce the same problems and difficulties as in any form of specific immunotherapy. Haber and Burton 5 have, over a number of years, reported the synthesis of renin substrate inhibitors. These are structural analogues of the terminal 14-amino acid sequence of renin substrate. However, these are relatively insoluble, species specific and often inactive in vivo. The recent pUblication 6 of "transitional state" renin substrate inhibitors potent both in vitro and in vivo holds great promise for the future.
Angiotensin 11 competitive vascular receptor antagonists have been available for about 10 years. I ,7 They are structural peptide analogues of angiotensin 11 with amino acid substitutions in positions 1 and 8. Substitution of sarcosine in position 1 significantly prolongs the half-life of these peptides, whereas substitution in position 8 converts them to antagonists. They have been extensively and successfully used to investigate the physiological and pathophysiological role of the reninangiotensin system. I Saralasin, sar l -ala 8angiotensin 11, has been administered to humans. Being a peptide, it has to be given intravenously and has a short duration of action. It has mainly been used in diagnosis of renovascular hypertension,8,9 to establish the role of the renin-angiotensin system in the pathogenesis of the hypertension of chronic renal failure, and angiotensin's contribution to the raised peripheral vascular resistance of congestive heart failure. However, saralasin is expensive to manufacture, is inactive orally and has a relatively short half-life of 20-40 minutes. Furthermore, most of the antagonists have a marked initial agonist action which complicates the interpretation of their effects.
Potent, specific, orally active angiotensinconverting enzyme inhibitors have recently superseded the angiotensin 11 competitive receptor antagonists.
ANGIOTENSIN-CONVERTING ENZYME
INHIBITORS Angiotensin-converting enzyme (ACE) is an ectoenzyme found on vascular endothelial cells throughout the body. IO It is found in high concentration in the lung, kidney and reproductive system. It is now known that ACE and kininase 11 (dipeptidase hydrolase, EC 3.4.15.1) are the same enzyme. ll This enzyme splits the carboxy terminal dipeptide from the inactive decapeptide angiotensin I to form the biologically active octapeptide angiotensin 11 as well as inactivating bradykinin by cleaving the carboxy terminal dipeptide. Thus, ACE is responsible for the production of the most potent vasoconstrictor, angiotensin 11, as well as destroying the potent vasodilator bradykinin.
The first inhibitors of ACE were discovered in the venom of the South American pit viper, Bothrops jararaca. In 1970, Ferreira et al.
showed that the active agents in snake venom were a series of peptides and Ondetti and his colleagues I2 ,13 isolated, determined the structure and synthesised these inhibitory peptides. The most potent of these peptides were the pentapeptide, BP5, SQ20,475 and the nonapeptide BP9, SQ20,881 or teprotide. They have been used clinically in the past in the diagnosis of renin-dependent forms of hypertension. 14, 15 However, they have to be administered intravenously, have a relatively short half-life and are expensive to make. Hence, their practical application is limited and they are not available for routine clinical use.
Ondetti, Rubin and Cushman l6 realised the need for a cheap, orally active, specific ACE inhibitor and, by a series of brilliant deductions, designed a series of mercaptoakyl proline derivatives which were potent ACE inhibitors. These inhibitors were based on considerations of the similarity of ACE to carboxypeptidase, a knowledge of the active site of ACE and that it was a zinc metalloenzyme plus information gained on the optimal carboxyterminal amino acids of the oligopeptide inhibitors. The prototype of this series of ACE inhibitors was 2-D-methyl-3 mercapto-propanyl-L-proline SQ 14,225, captopril (Capoten-R , Squibb). Its interaction with ACE is depicted in Figure 2 . Captopril is a simple substituted dipeptide containing a sulphydryl group important for binding to the zinc ligand in ACE. There are now many different ACE inhibitors, some dipeptides with sulphydryl groups similar to captopril (YS980, SA446), some substituted tripeptides without sulphydryl groups (MK421, Enalapril, Merck Sharp and Dohme, Figure 2 ), some phosphoryl derivatives and a ketomethylene tripeptide. 17 They all contain a terminal proline amino acid with varying substitutions and all act as competitive inhibitors of ACE. Captopril is the only ACE inhibitor available for clinical use but enalapril is currently undergoing phase III clinical trials.
Pharmacokinetics and Pharmacodynamics Is
Captopril is well absorbed (75070) from the gastrointestinal tract. About 70070 is proteinbound but because of the sulphydryl group it forms inactive dimers with reducing agents, particularly cysteine and methionine-containing endogenous compounds. Captopril has a rapid onset of action, within 20 minutes, a peak effect between 60-90 minutes, and lasts four to six hours. It is mainly excreted by the kidney by both glomerular filtration and tubular secretion, hence the dosage should be adjusted in patients with renal insufficiency.
Enalapril ( however, is well absorbed through the gut (61070) and is converted to the active compound MK421 diacid (MK422), mainly by the liver. Enalapril has a much longer duration of action than captopril -the maximal effect being four to six hours and lasting 24-36 hours. 19 ACE inhibitors have been shown to lower the blood pressure in normals and hypertensives by a reduction in total peripheral resistance. There is either no change in cardiac output or a slight increase, with rises in regional blood flow (brain, mesenteric, renal) ( Table 1) . Interestingly enough, there is no reflex tachycardia suggesting same concurrent effect on the baroreflex and the sympathetic nervous system. 20 .Ialdosterone 3.
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.Iurinary kallikrein 8. tprostaglandins The hormonal effects that have been reported 21 ,22 include suppression of plasma angiotensin Il and aldosterone with reciprocal rises in plasma angiotensin I and renin. There have been conflicting reports on changes in plasma bradykinin probably reflecting the role of kallikrein-kinin as a local hormonal system important in local blood flow regulation rather than as a circulating hormone. ACE inhibitors sometimes cause a small acute natriuresis and diuresis but long-term sodium balance appears normal.
The haemodynamic and hormonal effects have been shown to be very dependent on the sodium status of the subjects, probably due to activation of the renin-angiotensin system and angiotensin dependency of the blood pressure. The presence of sodium and volume depletion markedly enhances the hypotensive effect of ACE inhibitors.
The mechanism of the hypotensive action of ACE inhibitors is not clear. The acute hypotensive effect is probably mediated by the fall in angiotensin 11 levels and correlates reasonably well with basal plasma renin and angiotensin concentration. The long-term hypotensive effect seems more complicated and probably involves both blockade of the renin angiotensin system and enhancement of the kallikrein-kinin system. 23 Other mechanisms proposed also include changes in aldosterone and sodium balance, involvement of the prostaglandin system and indirect inhibition of the sympathetic nervous system.
CLINICAL USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS Hypertension
Captopril has now been shown by many clinical trials, including a double-blind study, to be effective long-term therapy in essential hypertension. 21 ,23-26 It is also very important in the treatment of drug-resistant hypertension, as well as severe accelerated hypertension. 25 . 27 ACE inhibitors are particularly useful in renovascular hypertension and in end-stage renal failure with dialysis-resistant hypertension. 28 Some specific indications for the use of ACE inhibitors in the treatment of hypertension are listed in Table 2 . The starting dose of captopril is usually 25 mg tds and enalapril 5-10 mg bd. However, this dose of captopril and enalapril should be reduced to 6.25 mg or less if there is sodium or volume depletion or in any high renin state to avoid a precipitous fall in blood pressure and even acute tubular necrosis. The hypotensive effect is rapid in onset with a progressive fall in blood pressure over the first hour. However, it may take two to three weeks to achieve a maximal hypotensive effect. The dose of captopril can be increased to a maximum of 150 mg tds and that of enalapril to 40 mg bd.
The hypotensive effect of ACE inhibitors and diuretics is additive. We have, therefore, found it more effective to either restrict the patient's salt intake or add a diuretic rather than increase the dose of captopril above 150 29 Congestive Heart Failure Angiotensin has been shown to significantly contribute to the raised total peripheral resistance found in congestive heart failure. With the advent of afterload reduction as a new mode of therapy for congestive heart failure, it was natural that ACE inhibitors would be tried. 30 They have proved to be spectacularly successful. Treatment with captopril or enalapril in drug-resistant congestive heart failure has been demonstrated to be very effective.
The patients improve symptomatically, and significant short-and long-term haemodynamic improvement has been documented. Generally, there is a fall in left and right heart pressures, a fall in the jugular venous pressure, and total peripheral resistance together with a reciprocal rise in cardiac output. These haemodynamic changes may be associated with a fall in blood pressure which, surprisingly, rarely produces significant postural symptoms. However, low blood pressure is a relative contraindication to the use of ACE inhibitors in heart failure and sometimes requires cessation of therapy. Unlike other vasodilators, ACE inhibitors apparently do not cause reflex tachycardia, activation of the sympathetic nervous system or tolerance. Furthermore, they potentiate the diuretic and natriuretic effect of diuretics, often inducing diuresis in resistant patients at the same time as preventing the secondary hyperaldosteronism and hypokalaemia induced by diuretics. Currently, ACE inhibitors are the treatment of choice for afterload reduction in congestive heart failure.
Side-effects
The following side-effects have been reported with captopril: rash and fever (13070), aguesia or loss of taste (8%), proteinuria (2%), membranous glomerulonephritis (0.3%), neutropenia, agranulocytosis (0.6%). The sideeffects are dose-dependent and reversible. They are similar to those reported for penicillamine and, therefore, raise the possibility that they may be related to the sulphydryl group in captopril rather than its ACE inhibition.
To date, few side-effects have been reported for enalapril which does not contain a sulphydryl group. However, experience is limited and isolated reports of neutropenia and scalded mouth have appeared.
RENAL FUNCTION AND ACE INHIBITORS
In both experimental animals and man, ACE inhibitors produce renal vasodilation with a rise in renal blood flow, a reciprocal fall in renal vascular resistance without change in glomerular filtration rate. 29 ,31 Unlike most antihypertensive agents therefore, they tend to maintain renal function and therefore have a distinct advantage in treating hypertensive patients with renal insufficiency.
However, in patients with bilateral renal artery stenosis, or stenosis to a single kidney or transplant stenosis, administration of captopril may be associated with a dramatic rise in plasma creatinine. This phenomenon has byen reproduced experimentally in dogs. It presumably reflects angiotensin's intrarenal role in maintaining glomerular filtration pressure by efferent arteriolar constriction, removal of which by ACE inhibitors leads to a fall in glomerular pressure which cannot be compensated for by an increase in flow in the presence of a fixed arterial stenosis.
Anaesthesia and Intensive Care. Vol. 11, No. 4, November, 1983 ANAESTHESIA AND ACE INHIBITORS There are no intravenous forms of ACE inhibitors available for routine clinical use. Neither captopril nor enalapril have an intravenous formulation. However, the nonapeptide inhibitor BP9, SQl 20881 or teprotide can only be given intravenously and has been used successfully in humans in the past but only for diagnostic purposes. It would be possible to use this compound during surgical operations; however, the very short half-life of teprotide (20 minutes) precludes its use in the perioperative period.
Several of our patients being treated with captopril have come to emergency surgery without any harmful effects. Indeed, as hypotensive agents, ACE inhibitors have some useful pharmacological properties advantageous during anaesthesia and surgery. However, there are no controlled human studies on the effects of ACE inhibitors during anaesthesia. As stated in a previous section, they do not interfere with the autonomic nervous system and, hence, normal sympathetic responses to posture, tilting, exercise, anaesthesia and haemorrhage occur. However, it needs to be remembered that the reninangiotensin system plays a significant role in response to haemorrhage and helps maintain the blood pressure during acute bleeding.
There is some evidence that ACE inhibitors may indirectly interfere with the sympathetic nervous system. Vascular vasoconstrictor responses to sympathetic nerve stimulation are decreased by captopril while responses to noradrenaline remain unaltered. These effects appear to be organ-selective as cardiac sympathetic responses are retained. 32 It is probable that some interaction between the sympathetic nervous system and ACE inhibitors occurs because of angiotensin's role in facilitating noradrenaline release from sympathetic nerve terminals.
Enkephalinase is a similar carboxydipeptidase to ACE, responsible for the degradation of enkaphalins, and which in vitro can be inhibited by high doses of captopril. Preliminary work in animals 33 indicates that captopril may potentiate morphine-induced depression of the respiratory rate, possibly by inhibition of the degradative enzyme enkephalinase. This potential drug interaction has not been a clinical problem in the management of our patients requiring anaesthesia or analgesia.
ACE inhibitors should also be administered cautiously to saline-and volume-depleted patients to avoid precipitous falls in their blood pressure. Similarly, patients who have been treated with sympatholytic agents tend to have larger falls in their blood pressure 23 with concomitant administration of ACE inhibitors, presumably because, in these patients, the sympathetic nervous system is unable to compensate for the fall in blood pressure following ACE inhibitors. Thus, autonomic nervous system-blocking drugs should be ceased for several days prior to captopril administration. There are, as yet, no other reported serious drug interactions with ACE inhibitors.
In conclusion, it is too early to ascribe the overall place of ACE inhibitors in the management of hypertension but they offer an exciting new development in the treatment of hypertension and heart failure.
